The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector

[1]  Qingyuan Du,et al.  Candidate , 2012, Juan Perón.

[2]  E. Nelson,et al.  Anticancer Mechanisms in Two Murine Bone Marrow–Derived Dendritic Cell Subsets Activated with TLR4 Agonists , 2018, The Journal of Immunology.

[3]  M. Sedegah,et al.  Development of replication-deficient adenovirus malaria vaccines , 2017, Expert review of vaccines.

[4]  D. Montefiori,et al.  Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. , 2016, Vaccine.

[5]  S. Reed,et al.  The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. , 2016, Current opinion in immunology.

[6]  R. Coler,et al.  Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites , 2016, Clinical and Vaccine Immunology.

[7]  A. Kamen,et al.  Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. , 2016, Vaccine.

[8]  Yushi Yao,et al.  Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens , 2016, Molecular therapy. Methods & clinical development.

[9]  S. Nitayaphan,et al.  Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition , 2016, AIDS.

[10]  K. Ishii,et al.  TANK-binding kinase 1-dependent or -independent signaling elicits the cell-type-specific innate immune responses induced by the adenovirus vector. , 2016, International immunology.

[11]  D. E. Parks,et al.  A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations , 2016, PloS one.

[12]  Man Li,et al.  Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant. , 2016, Molecular pharmaceutics.

[13]  D. Barouch,et al.  Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses , 2016, Journal of Virology.

[14]  T. Seya,et al.  Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy , 2016 .

[15]  E. Wakeland,et al.  Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation , 2015, Proceedings of the National Academy of Sciences.

[16]  Daniel E. Zak,et al.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. , 2015, The Journal of clinical investigation.

[17]  D. Logunov,et al.  Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer , 2014, Journal of Translational Medicine.

[18]  A. Salazar,et al.  Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine. , 2014, Virology.

[19]  R. M. Khaitov,et al.  Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors , 2014, Acta naturae.

[20]  D. Kaufman,et al.  Longitudinal Requirement for CD4+ T Cell Help for Adenovirus Vector–Elicited CD8+ T Cell Responses , 2014, The Journal of Immunology.

[21]  J. Taube,et al.  Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab , 2014, Journal of Translational Medicine.

[22]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[23]  L. Picker,et al.  Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein–Induced T Cell Responses In Nonhuman Primates , 2013, The Journal of Immunology.

[24]  C. Scallan,et al.  Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. , 2013, Vaccine.

[25]  W. Tan,et al.  Poly(I:C)/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine Boosting , 2013, PloS one.

[26]  C. Scallan,et al.  An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models , 2012, Clinical and Vaccine Immunology.

[27]  R. Hancock,et al.  Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. , 2012, Vaccine.

[28]  S. Gilbert,et al.  T‐cell‐inducing vaccines – what’s the future , 2012, Immunology.

[29]  Kapil Bahl,et al.  Type 1 Interferons and Antiviral CD8 T-Cell Responses , 2012, PLoS pathogens.

[30]  L. Davis,et al.  IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. , 2011, Blood.

[31]  J. Huber,et al.  Regulation of effector and memory T‐cell functions by type I interferon , 2011, Immunology.

[32]  A. Amalfitano,et al.  Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity , 2010, Clinical and Vaccine Immunology.

[33]  B. Pulendran,et al.  Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors , 2010, Journal of Virology.

[34]  Nathaniel L. Simmons,et al.  TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector , 2010, Journal of Virology.

[35]  Darin F. Quach,et al.  A New Adenovirus Based Vaccine Vector Expressing an Eimeria tenella Derived TLR Agonist Improves Cellular Immune Responses to an Antigenic Target , 2010, PloS one.

[36]  I. M. Belyakov,et al.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. , 2010, The Journal of clinical investigation.

[37]  E. Miyaji,et al.  Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. , 2009, Vaccine.

[38]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[39]  Y. Wen,et al.  Biological features of hepatitis B virus isolates from patients based on full‐length genomic analysis , 2009, Reviews in medical virology.

[40]  S. Ngoi,et al.  Targeting Poly(I:C) to the TLR3-Independent Pathway Boosts Effector CD8 T Cell Differentiation through IFN-α/β1 , 2008, The Journal of Immunology.

[41]  Bryan R. G. Williams,et al.  Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.

[42]  V. Appay,et al.  CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.

[43]  J. Tommassen,et al.  Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. , 2008, Vaccine.

[44]  D. Karan,et al.  Paradoxical enhancement of CD8 T cell‐dependent anti‐tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine , 2007, International journal of cancer.

[45]  W. Gillanders,et al.  The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. , 2006, Vaccine.

[46]  Michael Y. Gerner,et al.  Signals required for programming effector and memory development by CD8+ T cells , 2006, Immunological reviews.

[47]  G. Ciliberto,et al.  CD8+ T‐Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T‐Cell Tolerance is Broken by Additional Co‐administration of a Toll‐Like Receptor Ligand , 2006, Scandinavian journal of immunology.

[48]  J. Curtsinger,et al.  Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells , 2003, The Journal of experimental medicine.

[49]  C. Janeway,et al.  The Toll receptor family and microbial recognition. , 2000, Trends in microbiology.

[50]  Sally R. M. Clarke,et al.  The critical role of CD40/CD40L in the CD4‐dependent generation of CD8+ T cell immunity , 2000, Journal of leukocyte biology.

[51]  M. Jenkins,et al.  Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. , 1999, Journal of immunology.

[52]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.